- Home
- LVTX vs ECOR Comparison
LVTX vs ECOR Comparison
Compare LVTX & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVTX
- ECOR
- Stock Information
- Founded
- LVTX 2016
- ECOR 2005
- Country
- LVTX Netherlands
- ECOR United States
- Employees
- LVTX N/A
- ECOR N/A
- Industry
- LVTX Biotechnology: Pharmaceutical Preparations
- ECOR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- LVTX Health Care
- ECOR Health Care
- Exchange
- LVTX Nasdaq
- ECOR Nasdaq
- Market Cap
- LVTX 34.2M
- ECOR 40.1M
- IPO Year
- LVTX 2021
- ECOR 2018
- Fundamental
- Price
- LVTX $1.31
- ECOR $6.02
- Analyst Decision
- LVTX Hold
- ECOR Strong Buy
- Analyst Count
- LVTX 3
- ECOR 2
- Target Price
- LVTX $3.17
- ECOR $25.50
- AVG Volume (30 Days)
- LVTX 61.1K
- ECOR 130.4K
- Earning Date
- LVTX 05-20-2025
- ECOR 05-07-2025
- Dividend Yield
- LVTX N/A
- ECOR N/A
- EPS Growth
- LVTX N/A
- ECOR N/A
- EPS
- LVTX N/A
- ECOR N/A
- Revenue
- LVTX $11,982,000.00
- ECOR $25,182,000.00
- Revenue This Year
- LVTX N/A
- ECOR $32.20
- Revenue Next Year
- LVTX N/A
- ECOR $46.27
- P/E Ratio
- LVTX N/A
- ECOR N/A
- Revenue Growth
- LVTX 77.01
- ECOR 57.09
- 52 Week Low
- LVTX $0.85
- ECOR $5.02
- 52 Week High
- LVTX $3.20
- ECOR $19.49
- Technical
- Relative Strength Index (RSI)
- LVTX 61.39
- ECOR 33.07
- Support Level
- LVTX $1.03
- ECOR $5.20
- Resistance Level
- LVTX $1.20
- ECOR $6.47
- Average True Range (ATR)
- LVTX 0.08
- ECOR 0.71
- MACD
- LVTX 0.00
- ECOR 0.33
- Stochastic Oscillator
- LVTX 87.50
- ECOR 49.26
About LVTX LAVA Therapeutics N.V.
LAVA Therapeutics NV is a biotechnology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer.
About ECOR electroCore Inc.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.